Adam C. Berger

Prof. Adam C. Berger

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
CDCatherine Hambleton Davis
Catherine Hambleton Davis
JHJason Ho
Jason Ho
RSRyan Stephenson
Ryan Stephenson
DADavid A. August
David A. August
HGHeather Gee
Heather Gee
Adam C. BergerAdam C. Berger
Adam C. Berger
PURPOSE: Many cancer centers engage in multidisciplinary tumor board meetings to determine the optimal approach to complex cancer care. With the onset of the COVID-19 pandemic, many institutions changed the format of these meetings from in-person to virtual. The aim of this study was to determine if the change to a virtual meeting format had an impact on attendance and cases presented. METHODS: Tumor board records were analyzed to obtain attendance and case presentation information at a National Cancer Institute–designated Comprehensive Cancer Center. Twelve-month in-person tumor board data were compared with 12-month virtual tumor board data to assess for difference in attendance and case presentation patterns. RESULTS: Seven separate weekly tumor board meetings at the beginning of the study (breast, GI, gynecology, liver, lung, melanoma, and urology) were expanded to nine meetings on the virtual platform (+endocrine and pancreas). Overall attendance increased by 46% on the virtual platform compared with in-person meetings (4,030 virtual attendances v 2,753 in-person, P < .001). Increased attendance was present across all specialties on the virtual platform. In addition, the number of patient cases discussed increased from 2,127 in in-person meeting to 2,656 on the virtual platform (a 20% increase, P < .001). CONCLUSION: A significant increase was observed in overall tumor board attendance and in case presentations per meeting, requiring the expansion of additional weekly meetings. Furthermore, in a major cancer center with multiple community affiliates, virtual tumor boards may encourage increased participation from remote sites with the benefit of obtaining expert specialist advice as compared with geographically challenging in-person meetings.

19 November 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CDCatherine H. Davis
Catherine H. Davis
JHJason Ho
Jason Ho
SGStephanie H. Greco
Stephanie H. Greco
VKVadim P. Koshenkov
Vadim P. Koshenkov
RVRoberto J. Vidri
Roberto J. Vidri
Adam C. BergerAdam C. Berger
Adam C. Berger

23 January 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
AKAaron W. Kangas-Dick
Aaron W. Kangas-Dick
AGAlissa Greenbaum
Alissa Greenbaum
VGVictor Gall
Victor Gall
RGRoman Groisberg
Roman Groisberg
JMJanice Mehnert
Janice Mehnert
VKVadim Koshenkov
Vadim Koshenkov

25 October 2022 in Cell Reports
Verified
Journal Article
Open access
MLMichelle Harreman Lehner
Michelle Harreman Lehner
JWJane Walker
Jane Walker
KTKotryna Temcinaite
Kotryna Temcinaite
AHAnna Herlihy
Anna Herlihy
MTMichael Taschner
Michael Taschner
JSJesper Q. Svejstrup
Jesper Q. Svejstrup
The “last resort” pathway results in ubiquitylation and degradation of RNA polymerase II in response to transcription stress and is governed by factors such as Def1 in yeast. Here, we show that the SMY2 gene acts as a multi-copy suppressor of DEF1 deletion and functions at multiple steps of the last resort pathway. We also provide genetic and biochemical evidence from disparate cellular processes that Smy2 works more broadly as a hitherto overlooked regulator of Cdc48 function. Similarly, the Smy2 homologs GIGYF1 and -2 affect the transcription stress response in human cells and regulate the function of the Cdc48 homolog VCP/p97, presently being explored as a target for cancer therapy. Indeed, we show that the apoptosis-inducing effect of VCP inhibitors NMS-873 and CB-5083 is GIGYF1/2 dependent.

1 January 2020 in Surgical Oncology Clinics of North America
Verified
Journal Article
Closed access
KAKimberly Aderhold
Kimberly Aderhold
MWMelissa Wilson
Melissa Wilson
Adam C. BergerAdam C. Berger
Adam C. Berger
SLShoshana Levi
Shoshana Levi
JBJoseph Bennett
Joseph Bennett

25 March 2021 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
VGVictor Gazivoda
Victor Gazivoda
AGAlissa Greenbaum
Alissa Greenbaum
JRJoshua Roshal
Joshua Roshal
JLJenna Lee
Jenna Lee
LRLekha Reddy
Lekha Reddy
Adam C. BergerAdam C. Berger
Adam C. Berger